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CRISPR-Cas9 edited pluripotent stem cell-derived macrophages, we have explored the potential 23 of a modified restriction factor (human TRIMCyp) to inhibit HIV-1 replication in both cell free 24 and cell-cell infection models. We show that the expression of TRIMCyp from the endogenous 25 TRIM5α locus potently restricts infection by cell-free HIV-1. Our results also show the 26 importance of the human cyclophilin A-HIV-1 capsid interaction for viral escape from restriction 27 by native human TRIM5α, highlighting the evolutionary interplay between virus and this host 28 restriction factor. However, when co-cultured with infected T cells, stem cell-derived 29 macrophages are primarily infected by fusion between the cells. We have termed infected cells 30 that result from these fusions heterocytia, and show that their formation overcomes multiple 31 restriction factors and the reverse transcriptase inhibitor AZT. 32 Importance 33 As sentinels of the immune system, macrophages are relatively resistant to infection by 34 pathogens such as HIV-1. However, infected macrophages are found in infected patients and 35 they play key roles in the pathogenesis of the disease as well as being a component of the viral 36 reservoir that must be targeted before treatment can become cure. In this article, we show that 37 some of the mechanisms by which macrophages restrict HIV-1 can be overcome through a 38 recently described cell-cell interaction leading to cell-cell fusion. We also highlight an Introduction 45 Tissue resident macrophages are important for homeostasis, development and protection from 46 invading pathogens (1). Their role against pathogens includes detection of pathogen-associated 47 molecular patterns (PAMPs) by their numerous pattern recognition receptors (PRRs), 48 inactivation of the pathogen, innate signalling via interferon to bolster the defences of 49 surrounding cells, and antigen presentation to initiate an adaptive immune response. However, 50 being at the first line of defence also makes subversion of macrophages an evolutionarily 51 successful strategy for pathogens. As expressers of both CD4 and CCR5, macrophages stand 52 alongside T cells as a natural host cell for HIV-1, and as a self-renewing population of tissue 53 resident cells they also constitute a long-lived, inaccessible reservoir of virus that hampers viral 54 clearance strategies (2). Consistent with their immune role, macrophages have several antiviral 55 mechanisms to prevent infection by retroviruses such as HIV-1, namely the constitutive 56 expression of retroviral restriction factors, e.g. TRIM5α and SAMHD1 (3). 57 TRIM5α binds to the viral capsid lattice of an incoming, retroviral core and results in early 5 The other major restriction factor expressed by macrophages, SAMHD1, is a deoxynucleotide 82 triphosphohydrolase enzyme (17) . The activity of SAMHD1, conversion of dNTPs into 83 deoxynucleosides (dNs), is essential to maintain balanced levels of dNTPs within cells, which is 84 required for genome stability in dividing cells, and is used to reduce the availability of dNTPs to 85 invading pathogens such as HIV and Leishmania in non-dividing cells (18) (19) (20) . In activated T 86 cells, SAMHD1 is both expressed poorly and inactivated by phosphorylation, thus it is unable to 87 inhibit HIV-1 infection (21) (22) (23) . In contrast, in terminally differentiated macrophages, SAMHD1 88 is expressed at high levels, is dephosphorylated, and reduces the levels of dNTPs to below the 89 level required by the viral RT enzyme for efficient reverse transcription (19) . Although HIV-1 90 has evolved to be able to replicate, albeit inefficiently, under these conditions, the virus has not 91 evolved a specific counter measure such as VPx of SIV and HIV-2 that targets SAMHD1 for 92 degradation (24), implying that HIV-1 infection is macrophage independent or that the virus has 93 evolved a novel way of bypassing this restriction. 94 In this report, we use CRISPR/Cas9 to alter the restriction factors TRIM5α and SAMHD1 in order 95 to investigate their impact on the infection of macrophages by HIV-1. By investigating both cell-96 free and cell-associated infection models we confirm the potency of these factors, but also 97 highlight cell fusion as a mechanism by which they can both be efficiently overcome within 98 tissue macrophages. For this work, we used pluripotent stem cell-derived macrophages ( To measure the impact of TRIMCyp in human cells expressed at levels comparable with 106 endogenous TRIM5α, we generated a pluripotent stem cell line containing a knock-in of human 107 CypA into exon 8 of TRIM5α using a double nicking CRISPR-Cas9 approach ( Fig 1A) (27). A single 108 clone was identified carrying the CypA insertion in both alleles of TRIM5, as demonstrated by 109 the single peaks of the sequencing trace ( Fig 1B) that correspond to the fusion of TRIM5 with 110 CypA at Serine 322 of TRIM5 (28). To observe the effect of human TRIMCyp on HIV-1 infection, 111 the pluripotent stem cells and their differentiated macrophage progeny (pMac) (29) were 112 exposed to increasing doses of a single-cycle GFP-expressing reporter virus, pseudotyped with 113 VSV-G. 114 Infectivity in both stem cells and pMacs was reduced by conversion of TRIM5α to TRIMCyp (Fig   115   1C+D , and FigS1A+S2A). As TRIMCyp is inserted into the TRIM5 locus it can be considered a 116 marker of TRIM5 expression in wild-type cells, thus reduced infectivity of gene-edited stem cells 117 indicates that TRIM5α is normally expressed in pluripotent stem cells, potentially as a 118 mechanism to prevent endogenous and exogenous retroviral infections of the embryo (30). In 119 pMacs, TRIMCyp has a more dramatic impact on infectivity than in stem cells, reducing 120 infection by 10-fold at most viral concentrations ( Fig S2A) . At higher concentrations of virus 121 (shown in Fig S2A) it is possible to observe the well-established saturation of TRIM-based 122 restriction, such as rhesus TRIM5α and owl monkey TRIMCyp (31). To demonstrate that the 123 reduction in infection, seen in Fig 1C+D and Fig S1A+2A, was due to the modification at the 124 7 TRIM5α locus and not to any off-target effect, the cells were treated with CsA during infection. 125 CsA prevents CypA from binding the viral capsid and is known to rescue HIV-1 infection in 126 TRIMCyp expressing cells. CsA has also been shown to reduce HIV-1 infectivity in human cells by 127 an incompletely understood mechanism that has been linked to HIV-1 genome detection by 128 cellular DNA detection pathways (9). In agreement with these data, our wild-type cells were 129 more resistant to infection after treatment with CsA ( Fig 1C+D, Fig S1B+S2B) , whereas 130 treatment of the gene edited stem cells and pMacs with CsA significantly inhibited restriction of 131 HIV-1 by TRIMCyp ( Fig 1C+D, Fig S1C+S2C) . 132 Human cyclophilin A protects HIV-1 from human TRIM5α 133 Other than overall size of effect, a major difference that is observed between the pluripotent 134 stem cell progenitors and the differentiated pMacs, is a disparity between the unmodified and 135 modified cells when both are treated with CsA ( Fig 1C+D) . If one compares the results of wild-136 type macrophages expressing human TRIM5α with those of CsA-treated TRIMCyp-expressing 137 cells (which express CsA-inactivated TRIMCyp, but no human TRIM5α) it would appear that 138 TRIM5α has little or no activity against HIV-1 ( Fig S1D+S2D) , confirming previously published 139 data (32). However, the comparison of HIV-1-infection in the isogenic TRIM5α and TRIMCyp 140 macrophages both in the presence of CsA, reveals a residual antiviral effect of TRIM5α. If 141 human TRIM5α did not bind HIV-1, and CsA prevented TRIMCyp from binding, then in the 142 presence of CsA both cells should have the same infectivity to HIV-1. However, as can be seen 143 in Fig 1D and Fig S2E, TRIM5α-expressing pMacs treated with CsA are more resistant to HIV-1 144 than CsA-treated TRIMCyp-expressing pMacs, suggesting an interaction of human TRIM5α with 145 the viral core when CypA binding is prevented. We hypothesise that HIV-1 has evolved to use 146 8 CypA, to alter its conformation, as an evasion strategy to escape TRIM5α restriction. However, 147 as stem cells did not show this phenotype ( Fig 1C and Fig S1E) the impact of TRIM5α on CypA-148 deficient viruses appears to be cell-type dependent, as has recently been shown for TRIM5α 149 function in Langerhans cells (33), possibly due to reduced effectiveness of downstream 150 effectors in stem cells (34). 151 As the infection results were obtained using an exogenous reporter (eGFP) virus pseudotyped 152 with VSV-G, an envelope that has been previously been shown to alter susceptibility to TRIM5α 153 restriction (33), we performed the same infection experiments in pMacs using three different 154 vectors that were pseudotyped with JRFL, a cognate macrophage-tropic HIV-1 envelope 155 protein. As the different vectors had different reporter genes (eGFP or luciferase) the results 156 were normalized to the infectivity of wild-type TRIM5α expressing cells. The results confirm 157 those of the VSV-G pseudotyped vectors, with a 10-fold reduction in infectivity in both CsA-158 treated wild-type cells and in TRIMCyp-expressing cells, but a recovery of infection with CsA 159 treatment of TRIMCyp-expressing cells over that of CsA-treated wild-type cells ( Fig 1E) . 160 To observe the impact of TRIMCyp in a more physiological setting, pMacs were exposed to wild-161 type replication-competent HIV-1 with a luciferase reporter expressed in the Nef open reading 162 frame (NL-LucR.T2A). Tracking the infection over a 5-day period shows a robust growth of HIV-1 163 in TRIM5α-expressing cells, but not in TRIMCyp-expressing cells (Fig 1F, inset) . Although CsA 164 could inhibit replication in TRIM5α-expressing cells, it was not able to significantly alter 165 infectivity of TRIMCyp expressing cells ( Fig 1F) , possibly due to the multifaceted way CypA is 166 employed by the virus and, therefore, multiple stages of the virus lifecycle that could be 167 affected by CsA (16, 35) . To directly investigate the hypothesis that CypA alters the susceptibility of HIV-1 to human 169 TRIM5α restriction, we generated pMacs knocked out for human TRIM5α using CRISPR/Cas9 170 ( Fig 1A) . Exposure of these cells to an HIV-1-based vector clearly confirms previous data 171 showing a lack of robust restriction of HIV-1 by endogenous human TRIM5α ( Fig 1G) . However, 172 in the presence of CsA the loss of infectivity observed with wild-type cells is abrogated by 173 removal of TRIM5α ( Fig 1G) , which genetically proves our hypothesis ( Fig S2F) . To confirm the 174 role of CypA in protection of HIV-1 from TRIM5α, the cells were exposed to the same reporter 175 vector but harbouring the P90A mutation in capsid that prevents CypA binding. In line with the 176 published literature, the P90A mutant is not affected by cell treatment with CsA, but in 177 agreement with our hypothesis, the P90A mutant is more infectious in TRIM5α-knockout pMacs 178 compared with wild-type cells ( Fig 1H) . 179 180 TRIMCyp is circumvented by cell fusion 181 As TRIM5α and TRIMCyp restriction can be overcome by saturation with incoming viral cores 182 (31), and it is known that cell-to-cell transmission (e.g. via a virological synapse) can result in 183 large quantities of viral material being transferred to the target cell (36, 37), we set out to 184 establish whether endogenous levels of TRIMCyp were sufficient to protect cells in the more 185 physiological setting of cell-cell contact. To test this, we employed the same experimental set 186 up that was used to demonstrate phagocytosis of infected T cells as a potential route for HIV-1 187 infection of macrophages (38), with some minor adjustments. As an initial experiment, NL-188 LucR.T2A infected Jurkat-R5 cells were co-cultured with wild-type or TRIMCyp macrophages for 189 10 6 hours and infection of the macrophages was assessed 7 days later (Fig 2A) . In contrast to the 190 data obtained by Baxter et al. 2014 , we did not see a significant difference between infection 191 levels in the presence or absence of the reverse transcriptase inhibitor AZT, even though in 192 experiments using cell-free virus, AZT reduced infection of the macrophages (Fig 2B) . To 193 investigate the reverse transcriptase-independent results further, and to show that the results 194 were not dependent on the genotype of the induced pluripotent stem cell donor, the 195 experiment was repeated using pMacs from three independent donors, using both AZT and the 196 fusion inhibitor, T20 or enfuvirtide (39). Once again, the level of infection was unaffected by 197 AZT, however T20 reduced the level of infection more than 10-fold ( Fig 2C) , indicating that HIV-198 1 envelope-driven fusion of the cells was the major cause of the observed infection, a process 199 that appears to be unaffected by TRIMCyp expression. 200 To test the hypothesis that T cell-macrophage fusion bypasses TRIM-based restriction in a more 201 physiological setting, PBMC-derived CD4+ T cells from three independent donors were infected 202 with NL-LucR.T2A and co-cultured with wild-type or TRIMCyp-expressing pMacs in the presence 203 of AZT, T20 and the IFN-signalling inhibitor Ruxolitinib (Rux). Again, the levels of infection were 204 not significantly altered by the presence of AZT, whereas T20 significantly reduced infection (Fig   205   2D ). Additionally, preventing IFN signalling enhanced infection, particularly in the TRIM5α 206 expressing cells ( Fig 2D) . By subtracting the background signal of fusion-induced infection (AZT 207 control), it is possible to observe replication of HIV-1 during and/or after the co-culture (Fig 2E) , 208 which highlights the significant impact of TRIMCyp expression as well as IFN in this 209 experimental setting. A Luminex® assay on the culture supernatants confirmed the release of 210 IFNα in untreated conditions and an elevation of the proinflammatory cytokine IL-1β, without 211 11 any impact on the other cytokines/chemokines assayed, e.g. the chemoattractant MCP-1 (Fig   212   2F ). 213 Upon observing the co-cultures of macrophages and PBMC-derived T cells by light microscopy it 214 became apparent that a major difference between the treatments was the absence of giant 215 syncytial cells in the T20 treated cells (Fig. 2G ). It has been known for many years that HIV-1-216 directed fusion between macrophages can result in giant multinucleated syncytia (40, 41) . 217 However, given that the majority of infection in the macrophages was independent of HIV-1 218 reverse transcription (AZT result in Fig. 2A+D ), we hypothesised that the major route of 219 macrophage infection in our experimental setting was T cell-macrophage fusion. To address 220 this, we performed live cell fluorescence microscopy on co-cultures of CellTracker TM Orange 221 CMRA-stained pMacs with T cells infected by an eGFP-expressing replication-competent HIV-1. 222 Within 30 minutes, fusion between T cells and macrophages was observed in the co-cultures, 223 with the eGFP-tagged HIV-1 Gag protein being rapidly transferred from the T cell to the 224 macrophage over a period of 5 minutes ( Fig 3A and Video S1). This process resulted in Fig S3B (38) ). Additional events included rapid loss of GFP signal 231 from the T cell in a process consistent with cell lysis ( Fig S3C) and transfer of virus from the T 232 cell to the macrophage in a process consistent with the formation of a virological synapse or 233 plasma membrane transfer between immune cells ( Fig S3D) (42, 43) . The only event that was 234 modified by antiviral drug treatment was cell fusion by T20, demonstrating that the results for 235 cell-cell infection (Fig 2A+C+D) were the outcome of the formation of a fusion of infected T cells 236 with uninfected macrophages; the product of which we have termed heterocytia, to distinguish 237 them from syncytia, derived from a single cell type, and heterokaryons, derived from 238 genetically different parents. 239 Heterocytia formation overcomes SAMHD1 restriction 240 Given the ability of heterocytia formation to overcome potent TRIMCyp restriction and to result 241 in infected macrophages without reverse transcription, we next investigated if the other major 242 antiretroviral mechanism employed by macrophages, SAMHD1, was also circumvented. We 243 have previously generated macrophages from pluripotent stem cells genetically ablated for the 244 retroviral restriction factor SAMHD1 (44). SAMHD1 knockout macrophages show faster and 245 more efficient infection by HIV-1 when exposed to NL-LucR.T2A virions ( Fig 3C) . However, 246 when cocultured with NL-LucR.T2A -infected T cells, the isogenic pairs of macrophages, 247 differing only by the presence of SAMHD1, show similar levels of infection ( Fig 3D) . This 248 infection is unaffected by AZT, but reduced by T20, which demonstrates that cell fusion not only 249 bypasses TRIM5α-mediated restriction but also SAMHD1 restriction, making it independent of 250 the major retroviral restriction factors and, therefore, potentially the most efficient method of 251 macrophage infection. 252 Given that in dividing cells SAMHD1 is inactivated by cyclin dependent kinase (CDK) 253 phosphorylation at T592 we hypothesized that cell fusion would also alter the regulation of 254 13 pMac SAMHD1. Within macrophages, SAMHD1 is generally unphosphorylated, and therefore 255 active, whereas in T cell lines such as CEM cells it is not expressed. Therefore, upon fusion 256 between the two cells, any detected increase in phosphorylated SAMHD1 would indicate an 257 interaction between the cells' proteomes. We co-cultured pMacs from three donors with a CEM 258 cell line constitutively expressing the HIV envelope, for 24 hours before lysing the cells and 259 probing for SAMHD1 phosphorylation by western blot. Quantification of the ratio of 260 phosphorylated SAMHD1 to total SAMHD1 shows that the pMac SAMHD1 is inactivated by 261 fusion with the T cell ( Fig 3E and Fig S4E) . 262 Heterocytia formation occurs in stem cell-derived microglia 263 To investigate the potential of T cells to fuse with microglia in the brain and thereby generate 264 giant cells, frequently observed in HIV encephalopathy, we employed our recently described infection, syncytium formation of in vitro-infected T cells has historically been linked to CXCR4-333 tropic viral strains that are also associated with more rapid disease progression (60). 334 Heterocytia have also been observed within ex vivo cultured T cell and dendritic cell co-cultures 335 from tonsil lymph nodes from infected individuals (61). In vivo evidence for the existence of TRIMCyp modification: The CRISPR-Cas9 plasmids used in this study were based on the dual guide 387 RNA (gRNA) and Cas9 D10A -expressing plasmid, pX335-U6-Chimeric_BB-CBh-hSpCas9 (pX335), and 388 its puromycin-resistance gene-expressing derivative, pX462(68) (gifts from Feng Zhang; Addgene 389 plasmids #42335 and #48141). Cloning was performed as previous described (68) LucR.T2A-infected T cells were added to day 7 differentiated pMacs at a ratio of 1:1, with or 455 without pre-treatment of pMacs with AZT (25 µM), T20 (7.5 µg/ml) or ruxolitinib (10 µM). After 456 6 hours co-culture, the T cells were removed with a single wash in PBS followed by incubation of 457 the cells in macrophage differentiation media supplemented with 25 µM etoposide for 7 days. 
